Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VKTXthis companyViking Therapeutics, Inc.	$29.23	-11.03×	6.2×	0×	-10.57×	-96.4%	0.0%	0.0%	0.0%	-56.3%	-61.5%	-7.0%	0×	0.46×	0×	9.33×	0.0%	1	2.31	1	C-
KLRAKailera Therapeutics, Inc.	$13.96	-20.63×	-8.6×	0×	-18.46×	-91.3%	0.0%	0.0%	0.0%	41.8%	-24.5%	-4.0%	-0.03×	0.95×	0×	12.01×	0.0%	—	—	2	C+
MBXMBX Biosciences, Inc. Common Stock	$54.61	-13.25×	3.12×	0×	-12.42×	-96.3%	0.0%	0.0%	0.0%	-23.6%	-26.5%	-7.1%	0×	0.86×	0×	24.62×	0.0%	1	55.59	2	C
MDGLMadrigal Pharmaceuticals, Inc.	$435.25	-45.32×	21.68×	13.63×	-49.99×	492.6%	94.1%	-31.3%	-30.1%	-47.8%	-31.6%	-1.5%	0.59×	-0.59×	-13.45×	4.01×	0.0%	1	6.22	2	C
SEPNSepterna Inc	$49.99	-25.35×	3.23×	26.85×	-24.05×	-143.8%	100.0%	-175.8%	-106.4%	-12.8%	-15.8%	8.9%	0.06×	2.05×	0×	4.73×	0.0%	3	7.9	2	C
VTVTvTv Therapeutics Inc.	$21.10	-12.5×	5.23×	0×	-7.98×	-50.1%	0.0%	0.0%	0.0%	-41.9%	-39.4%	-7.5%	0×	2.86×	-5,468×	13.54×	0.0%	2	1.49	1	C-
Peer median	—	-20.63×	3.23×	0×	-18.46×	-91.3%	0.0%	0.0%	0.0%	-23.6%	-26.5%	-4.0%	0×	0.95×	0×	12.01×	0.0%	2	7.06	2	—